| Title | Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China |
| Authors | Xu, Ruihua Wang, Wei Zhu, Bo Lin, Xiaoyan Ma, Dong Zhu, Lingjun Zhao, Qingchuan Nie, Yongzhan Cai, Xiaohong Li, Qi Fang, Weijia Li, Hongyan Wang, Ning Chen, Yun Peng, Cike Fang, Honghao Shen, Lin |
| Affiliation | Sun Yat Sen Univ, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China First Peoples Hosp Foshan, 81 North Lingnan Rd, Foshan 528000, Peoples R China Third Mil Med Univ, Xinqiao Hosp, 83 Xinqiaozheng St, Chongqing 400037, Peoples R China Fujian Med Univ, Union Hosp, 29 Xinquan Rd, Fuzhou 350001, Peoples R China Guangdong Gen Hosp, 106 Zhongshan Rd, Guangzhou 510245, Peoples R China Jiangsu Prov Hosp, 300 Guangzhou Rd, Nanjing 210029, Peoples R China Fourth Mil Med Univ, Xijing Hosp, 15 West Rd, Xian 710032, Changle, Peoples R China Sichuan Canc Hosp & Inst, 55 Sect 4,South Renmin Rd, Chengdu 610015, Peoples R China Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China First Hosp Zhejiang Prov, 79 Qingchun Rd, Hangzhou 310002, Peoples R China Eli Lilly & Co China, 288 Shi Men Yi Lu, Shanghai 200041, Peoples R China IQVIA, 968 West Beijing Rd, Shanghai 200063, Peoples R China Beijing Canc Hosp, 52 Fucheng Rd, Beijing 100142, Peoples R China |
| Keywords | CHANGING SITE DISTRIBUTION PROGNOSIS CHEMOTHERAPY |
| Issue Date | 18-Feb-2020 |
| Publisher | BMC CANCER |
| Abstract | Background Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China. Methods Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted. Results Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p < 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%). Conclusions Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018. |
| URI | http://hdl.handle.net/20.500.11897/621388 |
| DOI | 10.1186/s12885-020-6557-5 |
| Indexed | SCI(E) |
| Appears in Collections: | 待认领 |
